1
Tarran Jones
Mary M Bendig, Olivier J Leger, Jose Saldanha, Tarran S Jones, Ted A Yednock: Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodies. Elan Pharmaceuticals, Crowell & Moring, August 21, 2012: US08246958 (31 worldwide citation)

The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host ...


2
John P Anderson, Kirsten L Jacobson Croak, Sukanto Sinha: Assays for detecting .beta.-secretase. Elan Pharmaceuticals, Townsend & Townsend & Crew, August 24, 1999: US05942400 (99 worldwide citation)

Compositions comprising a novel protease capable of cleaving .beta.-amyloid precursor protein (APP) on the amino-terminal side of the .beta.-amyloid peptide therein are provided. The protease is designated .beta.-secretase. Reaction systems comprising .beta.-secretase may be used in screening assays ...


3
Peter A Seubert, Carmen Vigo Pelfrey, Dale B Schenk, Robin Barbour: Methods for aiding in the diagnosis of Alzheimers disease by measuring amyloid-.beta. peptide (x-.gtoreq.41). Elan Pharmaceuticals, Eli Lilly & Company, Carol A Stratford, Jean M Duvall, September 5, 2000: US06114133 (87 worldwide citation)

This invention provides methods useful in aiding in the diagnosis of Alzheimer's disease. The methods involve measuring the amount of amyloid-.beta. peptide (x-.gtoreq.41) in the cerebrospinal fluid of a patient. High levels of the peptide generally are inconsistent with a diagnosis of Alzheimer's. ...


4

5
Varghese John, Michel Maillard, Barbara Jagodzinska, James Beck, Andrea Gailunas, John Freskos, John Mickelson, Lakshman Samala, Jennifer Sealy, Ruth TenBrink, Lawrence Fang, Roy Hom: N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives. Elan Pharmaceuticals, Pharmacia & Upjohn Company, McDonnell Boehnen Hulbert & Berghoff, February 13, 2007: US07176242 (42 worldwide citation)

Disclosed are compounds of the formula wherein the variables RN, RC, R1, R25, R2, and R3 are as defined herein. These compounds have activity as inhibitors of beta-secretase and are therefore useful in treating a variety of discorders such as Alzheimer's Disease.


6
Susanna M S Chrysler, Sukanto Sinha, Pamela S Keim, John P Anderson, Hua Tan, Lisa Clair McConlogue: &bgr;-secretase antibody. Elan Pharmaceuticals, April 24, 2001: US06221645 (37 worldwide citation)

Compositions comprising a novel protease capable of cleaving &bgr;-amyloid precursor protein (APP) on the amino-terminal side of the &bgr;-amyloid peptide therein are provided. The protease is designated &bgr;-secretase. Reaction systems comprising &bgr;-secretase may be used in screening assays to ...


7
Arumugham Rasappa G, Prasad A Krishna: A&bgr; immunogenic peptide carrier conjugates and methods of producing same. Elan Pharmaceuticals, Wyeth, Arumugham Rasappa G, Prasad A Krishna, CELLI Rosemarie L, June 30, 2005: WO/2005/058941 (35 worldwide citation)

The present invention is directed to methods of producing conjugates of A&bgr; peptide immunogens with protein/polypeptide carrier molecules, which are useful as immunogens, wherein peptide immunogens are conjugated to protein carriers via activated functional groups on amino acid residues of the ca ...


8
Dale B Schenk, Robin M Barbour, Kelly L Johnson: Diagnostic methods for alzheimer's disease. Elan Pharmaceuticals, Lisabeth F Murphy, September 11, 2001: US06287793 (33 worldwide citation)

Methods are disclosed for the identification of key diagnostic antibodies and antigens characteristic of a disease state of interest. Key diagnostic antibodies and antigens, diagnostic kits, and methods for diagnosis, are disclosed for Alzheimer's disease.


9
Schenk Dale B, Masliah Eliezer: Prevention and treatment of synucleinopathic disease. Elan Pharmaceuticals, The Regents Of The University Of California, CELLI Rosemarie, May 21, 2004: WO/2004/041067 (31 worldwide citation)

The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. Th ...


10
Chilcote Tamie, Barbour Robin: Antibodies to alpha-synuclein. Elan Pharmaceuticals, Chilcote Tamie, Barbour Robin, LIEBESCHUETZ Joe, May 26, 2005: WO/2005/047860 (31 worldwide citation)

The invention provides methods for detecting alpha-synuclein. The invention also identifies preferred epitopes of alpha synuclein for use in such detection, and provides antibodies specifically binding to such epitopes.



Click the thumbnails below to visualize the patent trend.